Trinity Biotech Granted Extension to Meet Nasdaq Compliance

Trinity Biotech Granted Extension to Meet Nasdaq Compliance Requirements

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management solutions, has secured a crucial extension from Nasdaq, allowing it more time to demonstrate compliance with listing requirements. This move comes after the company received a deficiency letter on November 21, 2023, due to its market value of publicly held shares (MVPHS) falling below the necessary $15 million threshold for 30 consecutive business days.